AbobotulinumtoxinA in the management of cervical dystonia in the United Kingdom: a budget impact analysis

References

• BloudekLStacyMSchwartzMBrinMPapapetropoulosSCost of cervical dystonia in the United States [abstract]Movement Disorders201227Suppl 11005
   Google Scholar
• CoelhoMValdasAFMestreTFerreiraJJPain and quality of life in the treatment of cervical dystoniaEuropean Neurological Review2009427478
   Google Scholar
• MarrasCVan den EedenSKFrossRDMinimum incidence of primary cervical dystonia in a multiethnic health care populationNeurology200769767668017698789
   PubMed Web of Science ®Google Scholar
• VelickovicMBenabouRBrinMFCervical dystonia pathophysiology and treatment optionsDrugs200161131921194311708764
   PubMed Web of Science ®Google Scholar
• SteevesTDDayLDykemanJJetteNPringsheimTThe prevalence of primary dystonia: a systematic review and meta-analysisMov Disord201227141789179623114997
   PubMed Web of Science ®Google Scholar
• Epidemiological Study of Dystonia in Europe (ESDE) Collaborative GroupA prevalence study of primary dystonia in eight European countriesJ Neurol20002471078779211127535
   PubMed Web of Science ®Google Scholar
• AlbaneseAAsmusFBerardelliAEFNS MDS-ES Task ForceGuidelines for the Diagnosis and Treatment of Primary (Idiopathic) Dystonia EFNS MDS-ES Task Force. Available from http://www.movementdisorders.org/MDS-Files1/MDS-ES/guidelines_on_dystonia.pdfAccessed December 14, 2012
   Google Scholar
• The National Institute for Health and Clinical Excellence (NICE)Selective Peripheral Denervation for Cervical DystoniaLondon, UKThe National Institute for Health and Clinical Excellence2004
   Google Scholar
• WalkerFOBotulinum toxin therapy for cervical dystoniaPhys Med Rehabil Clin N Am2003144749766vi14580035
   PubMedGoogle Scholar
• JankovicJBotulinum toxin therapy for cervical dystoniaNeurotox Res200692–314514816785112
   PubMed Web of Science ®Google Scholar
• BurbaudPDucerfCCugyEBotulinum toxin treatment in neurological practice: how much does it really cost? A prospective cost-effectiveness studyJ Neurol201125891670167521424611
   PubMed Web of Science ®Google Scholar
• HilkerRSchischniaschviliMGhaemiMJacobsARudolfJHealth related quality of life is improved by botulinum neurotoxin type A in long term treated patients with focal dystoniaJ Neurol Neurosurg Psychiatry200171219319911459891
   PubMed Web of Science ®Google Scholar
• SkogseidIMMaltUFRøislienJKertyEDeterminants and status of quality of life after long-term botulinum toxin therapy for cervical dystoniaEur J Neurol200714101129113717708754
   PubMed Web of Science ®Google Scholar
• SlawekJFriedmanAPotulskaAFactors affecting the health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin type A injectionsFunct Neurol20072229510017637212
   PubMed Web of Science ®Google Scholar
• SkogseidIMRøislienJClaussenBKertyELong-term botulinum toxin treatment increases employment rate in patients with cervical dystoniaMov Disord200520121604160916114026
   PubMed Web of Science ®Google Scholar
• MolhoESAgarwalNReganKHigginsDSFactorSAEffect of cervical dystonia on employment: A retrospective analysis of the ability of treatment to restore premorbid employment statusMov Disord20092491384138719441129
   PubMed Web of Science ®Google Scholar
• BrockmannKSchweitzerKBeckGWachterTComparison of different preparations of botulinumtoxin A in the treatment of cervical dystoniaNeurology Asia201217115119
   Web of Science ®Google Scholar
• British National Formulary [webpage on the Internet]Joint Formulary CommitteeBritish National Formulary2012 Available from: https://www.medicinescomplete.com/mc/bnf/current/Accessed December 14, 2012
   Google Scholar
• Personal Social Services Research Unit [webpage on the Internet]Unit costs of health and social care 2011: compiled by Lesley CurtisKent, UKPersonal Social Services Research Unit2011 Available from: http://www.pssru.ac.uk/project-pages/unit-costs/2011/index.phpAccessed December 14, 2012
   Google Scholar
• ErjantiHMarttilaRRinneUThe prevalence and incidence of cervical dystonia in south-western FinlandMov Disord199611Suppl 1A215
   Google Scholar
• The Dystonia Society [webpage on the Internet]Cervical dystoniaLondon, UKThe Dystonia Society2014 Available from: http://www.dystonia.org.uk/index.php/professional-research/types-of-dystonia/cervical-dystoniaAccessed June 2, 2014
   Google Scholar
• MHRADysport Powder for Solution for Injection and Botulinum Toxin Type A Powder for Solution for Injection (Clostridium botulinum Type A Toxin – Haemagglutinin Complex). PL 34926/0014 and 0015Slough, UKUKPAR2011 Available from: http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con108612.pdfAccessed July 22, 2014
   Google Scholar
• MHRABotox (Botulinum Toxin Type A). PL 00426/0074-0110, PL 00426/0118-0030, PL 00426/0119-0012Slough, UKUKPAR2012 Available from: http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con208720.pdfAccessed July 22, 2014
   Google Scholar
• MHRAXeomin 100 LD50 Units Powder for Solution for InjectionSlough, UKUKPAR2012 Available from: http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1427432040685.pdfAccessed July 22, 2014
   Google Scholar
• HanYStevensADashtipourKHauserRMariZA mixed treatment comparison (Mtc) to compare the efficacy of botulinum toxin type A treatments for cervical dystoniaValue Health2014173A57
   Web of Science ®Google Scholar
• AlbaneseAAbbruzzeseGDresslerDPractical guidance for CD management involving treatment of botulinum toxin: a consensus statementJ Neurol Epub201541
   Web of Science ®Google Scholar
• HubbleJSchwabJHubertCAbbottCCDysport (botulinum toxin type A) in routine therapeutic usage: a telephone needs assessment survey of European physicians to evaluate current awareness and adherence to product labeling changesClin Neuropharmacol201336412212723783005
   PubMed Web of Science ®Google Scholar
• MarchettiAMagarRFindleyLRetrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE studyMov Disord200520893794415810022
   PubMed Web of Science ®Google Scholar
• MisraVPEhlerEZakineBMaisonobePSimonetta-MoreauMINTEREST IN CD groupFactors influencing response to Botulinum toxin type A in patients with idiopathic cervical dystonia: results from an international observational studyBMJ Open201223piie000881
   Web of Science ®Google Scholar